New hope for kids with severe psoriasis: QLETLI biosimilar under study
NCT ID NCT05803187
First seen Mar 14, 2026 · Last updated Jun 23, 2026 · Updated 13 times
Summary
This study looked at how well and how safely QLETLI, a biosimilar of adalimumab, works for children and teens aged 4 to 17 with severe plaque psoriasis. A total of 80 participants were followed for 24 weeks. The main goal was to see if the drug could significantly reduce psoriasis symptoms, as measured by standard skin scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, 200072, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QLETLI (adalimumab biosimilar)
What this could lead to
If successful, this could confirm that QLETLI is a safe and effective option for controlling severe psoriasis in children and teens.
What could go wrong
This is a completed observational study, not a randomized trial, so results may be less definitive. Psoriasis often requires ongoing treatment, and side effects like infections are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.